Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 7,390 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Myeloid Leukemia
Interventions
Idasanutlin, Cytarabine, Daunorubicin, Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 9 more
Conditions
Phenylketonuria, PAH Deficiency
Interventions
HMI-102
Genetic
Lead sponsor
Homology Medicines, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Conditions
Ischemic Heart Disease
Interventions
GS-6615, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Parathyroid Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Thyroid Cancer, Recurrent Verrucous Carcinoma of the Larynx, Stage III Follicular Thyroid Cancer, Stage III Papillary Thyroid Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Larynx, Stage IIIB Non-small Cell Lung Cancer, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVA Basal Cell Carcinoma of the Lip, Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Follicular Thyroid Cancer, Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Lymphoepithelioma of the Oropharynx, Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVA Papillary Thyroid Cancer, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVB Basal Cell Carcinoma of the Lip, Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Follicular Thyroid Cancer, Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Lymphoepithelioma of the Oropharynx, Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVB Papillary Thyroid Cancer, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVC Basal Cell Carcinoma of the Lip, Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Follicular Thyroid Cancer, Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Lymphoepithelioma of the Oropharynx, Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVC Papillary Thyroid Cancer, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Thryoid Gland Nonmedullary Carcinoma, Thyroid Gland Medullary Carcinoma, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
gefitinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Advanced Solid Tumors
Interventions
Paclitaxel, RO5509554
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Conditions
Advanced Non-hematologic Malignancies
Interventions
IXAZOMIB
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
6
States / cities
Tampa, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more
Terminated No phase listed Observational

VIZ ACCESS HCM - Multi-Site Registry

NCT07103057
Conditions
Hypertrophic Cardiomyopathy
Interventions
Viz HCM
Device
Lead sponsor
Viz.ai, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Evanston, Illinois • Philadelphia, Pennsylvania
Conditions
Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Cyclophosphamide, JAK Inhibitor, Fludarabine, Recombinant Granulocyte Colony-Stimulating Factor, Melphalan, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Computed Tomography, Magnetic Resonance Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Terminated Not applicable Interventional Results available

Triathlon Tritanium Knee Outcomes Study

NCT02155712
Conditions
Arthroplasty, Replacement, Knee
Interventions
Triathlon Tritanium Knee, Triathlon Knee
Device
Lead sponsor
Stryker Orthopaedics
Industry
Eligibility
18 Years to 75 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
10
States / cities
Gilbert, Arizona • Tucson, Arizona • Jacksonville, Florida + 7 more
Conditions
Pancreatic Cancer, Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Neoplasms
Interventions
anti-EGFR-bispecific antibody armed activated T-cells
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
New York, New York • Charlottesville, Virginia
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma, Cyclin-dependent Kinase 12 Mutated Tumors, Basal Cell Carcinoma (Unresectable or Metastatic), Sarcomatoid Renal Cell Carcinoma, Clear Cell Ovarian or Endometrial Carcinoma, Anal Carcinoma, Squamous Cell Penile Carcinoma, DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)
Interventions
INCB099318
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Hackensack, New Jersey • Greenville, South Carolina • Nashville, Tennessee
Conditions
Pediatric ALL
Interventions
ZTI-01 100 mg/kg, ZTI-01 75 mg/kg
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
Up to 11 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
5
States / cities
Orange, California • San Diego, California • Louisville, Kentucky + 2 more
Conditions
Healthy, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
HM12460A, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Ductal Carcinoma In Situ
Interventions
Sentinel lymph node biopsy (SLNB)
Procedure
Lead sponsor
Yale University
Other
Eligibility
67 Years to 94 Years · Female only
Enrollment
28,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Consolidation Therapy, Functional Magnetic Resonance Imaging, Gastrointestinal Endoscopy, Magnetic Resonance Imaging, Papaverine, Radiation Therapy, Total Mesorectal Excision
Procedure · Drug · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Completed Not applicable Interventional Accepts healthy volunteers

Music Mindfulness Study 2a.

NCT06505226
Conditions
Mental Health Issue, COVID-19
Interventions
in person meditation, in person meditation using headphones, virtual meditation
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut
Conditions
Mucopolysaccharidosis I
Interventions
AGT-181 (HIRMAb-IDUA)
Drug
Lead sponsor
ArmaGen, Inc
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Oakland, California • Orange, California • Decatur, Georgia + 3 more
Conditions
Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Interventions
Idelalisib, Rituximab, Bendamustine, Ofatumumab, Fludarabine, Everolimus, Bortezomib, Chlorambucil, Lenalidomide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
11
States / cities
Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Completed Phase 1 Interventional Results available

Assessment of KAN-101 in Celiac Disease (ACeD)

NCT04248855
Conditions
Celiac Disease
Interventions
KAN-101, Placebo
Drug
Lead sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Anaheim, California • Walnut Creek, California • Aventura, Florida + 10 more
Conditions
Digestive System Disease
Interventions
PvP001 placebo, PvP001 100 mg, PvP001 300 mg, PvP001 900 mg, Maximum Feasible Dose (MFD) of PvP002, Maximum Tolerated Dose (MTD) of PvP001, MTD of PvP001 following 7 days of PPI treatment, PvP002 placebo, PvP001 600 mg, PvP003 placebo, PvP003, PvP003 150 mg
Other · Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Anaheim, California
Conditions
Thrombosis, Cancer, Pulmonary Embolism
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Boston, Massachusetts + 4 more
Conditions
Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer
Interventions
Lurbinectedin, Osimertinib
Drug
Lead sponsor
Misty Shields
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Cytokine Release Syndrome
Interventions
ST266
Biological
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Clearwater, Florida • Chicago, Illinois • Chattanooga, Tennessee